🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT03559114
Recruiting Phase 3

PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)

NCT03559114 · tracked via the Priya Life Science Canada tracker
Phase
Phase 3
Started
2018-07-19
Last updated
2024-09-19

Condition(s) studied

Traumatic Brain Injury

Investigational drug(s) / intervention(s)

Dalteparin →Saline

Dalteparin: Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.

Saline: Saline in prophylactic doses administered daily if screening criteria are satisfied.

Study summary

This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria The pragmatic nature of this study seeks to include all consecutive patients presenting with significant TBI, regardless of whether ICB is evident at presentation. Inclusion criteria are the following: i) Patients with severe TBI defined as GCS of ≤8, or ii) Patients with moderate TBI defined as GCS = 9-12, admitted to ICU, with at least some ICB present on initial CT scan and any of the following: 1. Requiring invasive mechanical ventilation at the time of screening 2. Increased ICB on repeat CT scan compared to initial CT scan iii) Upon randomization the patient will be able to receive the first dose of study drug in the first 3 calendar days from the time of injury iv) ≥ 18 years of age Exclusion Criteria All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: i) Known Hypersensitivity to FRAGMIN (Dalteparin), or its constituents including benzyl alcohol or to other low molecular weight heparins and/or heparins or pork products ii) Known history of confirmed or suspected immunologically-mediated heparin-induced thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a known history of a positive in vitro platelet-aggregation test in the presence of FRAGMIN (Dalteparin) is positive iii) Known septic endocarditis iv) Uncontrollable active bleeding v) Known major blood clotting disorders vi) Known acute gastroduodenal ulcer (with active bleeding) vii) Severe uncontrolled hypertension (i.e. BP\>210 despite medications) viii) Known diabetic or hemorrhagic retinopathy ix) Anticipated to be unable to receive SCD on at least one lower extremity due to nature of injuries for duration of intervention period x) Presence of another confounding factor that can adequately explain the poor GCS at time of presentation (e.g. drug toxicity, seizure) xi) Known presence of irreversible coagulopathies xii) Known Pregnancy xiii) Participants extremely low weight (\<45 kg), or extremely high weight (\>120kg) xiv) Not expected to survive more than 48 hours from admission

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
Foothills Medical Centre Calgary Alberta Recruiting
Royal Alexandra Hospital Edmonton Alberta Recruiting
University of Alberta Hospital Edmonton Alberta Recruiting
Vancouver General Hospital Vancouver British Columbia Recruiting
Queen Elizabeth II Health Sciences Centre Halifax Nova Scotia Recruiting
Hamilton Health Sciences Centre Hamilton Ontario Recruiting
Kingston General Hospital Kingston Ontario Recruiting
The Ottawa Hospital Ottawa Ontario Recruiting
Sunnybrook Health Science Centre Toronto Ontario Recruiting
Unity Health Toronto Toronto Ontario Recruiting
Hopital de L'Enfant-Jesus Québec Quebec Recruiting
Royal University Hospital Saskatoon Saskatchewan Recruiting

More Sunnybrook Health Sciences Centre trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03559114 on ClinicalTrials.gov ↗ ← All trials in Canada